2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 487

Third Generation Anti-cyclic Citrullinated Peptide Antibodies Improve Prediction of Clinical Arthritis in Second Generation Anti-cyclic Citrullinated Peptide Positive Subjects at Risk of Rheumatoid Arthritis
Abstract Number: 86

THOR-809: An IL-2 Engineered from an Expanded Genetic Alphabet for the Potential Treatment of Autoimmune Disorders
Abstract Number: 1042

Thy-1 (CD90) as a Novel Marker for Tracking in Vivo Skin Fibrosis
Abstract Number: 2432

Thymic Stromal Lymphopoietin (TSLP) as a Biomarker of Primary Sjögren’s Syndrome (pSS) and Related Lymphoma: Results in Independent Cohorts
Abstract Number: 2129

Thyroperoxidase Antibodies in Patients with Positive ANA
Abstract Number: 1821

Tildrakizumab Efficacy for Psoriatic Arthritis: 24-week Analysis of Swollen and Tender Joint Counts and Pain
Abstract Number: 1524

Tildrakizumab Efficacy on Psoriasis in Patients with Psoriatic Arthritis—An Analysis from a Phase 2 Study
Abstract Number: 1798

Time to Bridge the Gap in Rheumatology Education: Interactive Team Based Learning Is Most Effective in Increasing Internal Medicine Residents’ Knowledge
Abstract Number: 1428

Time to Discontinuation of Tofacitinib in Rheumatoid Arthritis Patients with and Without Methotrexate: Results from a Rheumatoid Arthritis Cohort
Abstract Number: 1838

Time to Flare in Patients with New-Onset versus Relapsing Giant Cell Arteritis Treated with Tocilizumab or Placebo Plus Prednisone Tapering: 3-Year Results from a Randomized Controlled Phase 3 Trial
Abstract Number: 2518

Time to Lupus Low Disease Activity State: Role of African-American Ethnicity
Abstract Number: 426

Time to Response for Clinical and Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Tofacitinib, Adalimumab, or Placebo
Abstract Number: 2047

Time-trends in Opioid Use Hospitalizations in Common Musculoskeletal Conditions: Gout, Osteoarthritis, Rheumatoid Arthritis, Fibromyalgia, and Low Back Pain
Abstract Number: 312

Timely Glucocorticoid Tapering in Vasculitis: A Need for Improved Knowledge Translation to Limit Toxicity
Abstract Number: 885

TLR9 Signaling in HCV-Associated Atypical Memory B Cells Triggers Th1 and Rheumatoid Factor Autoantibody Responses

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].